CTLA4 and prostate cancer: Finally, a pilot phase 1 study (NCT03532217) is recruiting patients with metastatic castration-sensitive prostate cancer to investigate the effects of PROSTVAC in combination with a DNA vaccine encoding patient-specific neoantigens and checkpoint blockade (anti-CTLA-4 plus anti-PD-1).